Article in Microorganisms, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed.
Pharmaceuticals (Basel, Switzerland) · 2025
Article
Frontiers in cellular and infection microbiology · 2025
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Diego Garcia MirandaMultimaterials and Interfaces Laboratory (LMI), CNRS UMR 5615, University Claude Bernard Lyon 1, University of Lyon, 6 rue Victor Grignard, 69622 Villeurbanne, France.ORCID 0000-0003-3804-7632
Lucas de Paula RamosLaboratory "Health Systemic Process" (P2S), UR4129, Faculty of Medicine Laennec, University Claude Bernard Lyon 1, University of Lyon, 7 rue Guillaume Paradin, 69008 Lyon, France.ORCID 0000-0002-2682-2796
Nina AttikMultimaterials and Interfaces Laboratory (LMI), CNRS UMR 5615, University Claude Bernard Lyon 1, University of Lyon, 6 rue Victor Grignard, 69622 Villeurbanne, France.ORCID 0000-0002-8301-498X
Thaís Cristine PereiraDepartment of Biosciences and Oral Diagnosis, Institute of Science and Technology, São Paulo State University, Francisco José Longo 777, São José dos Campos 12245-000, SP, Brazil.
Luciane Dias de OliveiraDepartment of Biosciences and Oral Diagnosis, Institute of Science and Technology, São Paulo State University, Francisco José Longo 777, São José dos Campos 12245-000, SP, Brazil.ORCID 0000-0001-9956-7768
Maria Cristina MarcucciDepartment of Biosciences and Oral Diagnosis, Institute of Science and Technology, São Paulo State University, Francisco José Longo 777, São José dos Campos 12245-000, SP, Brazil.ORCID 0000-0002-8065-5618
Flavia Pires RodriguesOral Biology Division, School of Dentistry, Faculty of Medicine and Health, University of Leeds, Leeds LS2 9LU, UK.
Graziella Nuernberg Back BritoChristian Life University Foundation, Estrada Municipal do Pinhão do Borba, Pindamonhangaba 12412-825, SP, Brazil.
Florence CarrouelFaculté d'Odontologie, University Claude Bernard Lyon 1, University of Lyon, 7 rue Guillaume Paradin, 69008 Lyon, France.ORCID 0000-0002-6823-1636
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
The World Health Organization (WHO) has prioritized developing new drugs against specific bacteria and fungi, such as
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.